What are the side effects of Secukinumab?

Secukinumab (Secukinumab) is a human interleukin-17A antagonist indicated for patients 6 years of age and older with moderate to severe plaque psoriasis and is a candidate for systemic treatment or phototherapy. Also indicated for active psoriatic arthritis (PsA) in patients 2 years of age and older, adults with active ankylosing spondylitis (AS), and active nonradiographic axial spondyloarthritis (nr-axSpA), including objective signs of inflammation. Secukinumab also treats active enthesitis-associated arthritis (ERA) in patients 4 years of age and older.

Very common (experienced by more than 10% of people) side effects include upper respiratory tract infection, and Common (experienced by 1 to 10% of people) include oral herpes, runny nose, and diarrhea. In clinical trials, rare cases of allergic reactions, serious infections, and some serious inflammatory bowel disease occurred, some of which were new and some of which were worsening of existing conditions. Adverse reactions experienced post-marketing include skin and subcutaneous tissue disorders such as eczematous rashes (atopic dermatitis-like rash, dyshidrotic eczema, and erythroderma).

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.